Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Steven E. Lipshultz(Jacobs Institute), Steven D. Colan(Boston Children's Hospital), Marshall A. Schorin(Inova Fairfax Hospital), Luis A. Clavell(San Juan City Hospital), Eric Larsen(University of Massachusetts Chan Medical School), E. John Orav(Harvard University), Elly Barry, Uma H. Athale(McMaster University), Lewis B. Silverman(Columbia University Irving Medical Center), Albert Moghrabi(Centre Hospitalier Universitaire Sainte-Justine), Barbara L. Asselin(University of Rochester Medical Center), Stuart R. Lipsitz(Brigham and Women's Hospital), Bruno Michon(Centre hospitalier universitaire de Québec), Stephen E. Sallan, Rebecca E. Scully(Brigham and Women's Hospital), Yvan Samson(Centre hospitalier universitaire de Québec), Harvey J. Cohen(Lucile Packard Children's Hospital), Tracie L. Miller(University of Missouri–Kansas City), Donna Neuberg(Otsuka (Japan))
The Lancet Oncology
September 17, 2010
Cited by 452


Related Papers